Last update 23 Dec 2025

JNJ-87704916

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
JNJ-4916, JNJ-87704916, JNJ4916
Target-
Action-
Mechanism-
Therapeutic Areas
Neoplasms
Active Indication
Advanced Malignant Solid NeoplasmSolid tumor
Inactive Indication-
Originator Organization
Johnson & JohnsonJohnson & Johnson
Active Organization
Johnson & Johnson Enterprise Innovation, Inc.Johnson & JohnsonJohnson & Johnson
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with JNJ-87704916
NCT06311578
/ RecruitingPhase 1
Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
100 Clinical Results associated with JNJ-87704916
Login to view more data
100 Translational Medicine associated with JNJ-87704916
Login to view more data
100 Patents (Medical) associated with JNJ-87704916
Login to view more data
100 Deals associated with JNJ-87704916
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
United States
Johnson & Johnson Enterprise Innovation, Inc.
10 Apr 2024
Advanced Malignant Solid NeoplasmPhase 1
Canada
Johnson & Johnson Enterprise Innovation, Inc.
10 Apr 2024
Advanced Malignant Solid NeoplasmPhase 1
France
Johnson & Johnson Enterprise Innovation, Inc.
10 Apr 2024
Advanced Malignant Solid NeoplasmPhase 1
Spain
Johnson & Johnson Enterprise Innovation, Inc.
10 Apr 2024
Solid tumorPreclinical
United States
Johnson & JohnsonJohnson & Johnson
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ESMO2025
Phase 1
Advanced Malignant Solid Neoplasm
22
ufwjqxucyr(yjxhwcnszt) = The most frequently reported JNJ-4916-related toxicities were Pyrexia (18%), Nausea (14%) and flu-like symptoms (14%), all of Grade 1-2 severity. One patient experienced transient Gr 4 AST elevation and reported Gr 3 viremia after injection of a liver metastasis with concomitant detection of all 4 payloads in serum. pvgwedfcux (zllwjtshzp )
Positive
17 Oct 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free